Regenxbio earnings were -$196.4M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest RGNX earnings report on Jun 30, 2026 announced Q2 2026 earnings of $22.7M, down 125.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RGNX reported annual earnings of -$193.9M, with -14.6% growth.
On RGNX's earnings call on Aug 6, 2026, Regenxbio (NASDAQ: RGNX) reported Q2 2026 earnings per share (EPS) of $0.43, up 131.16% year over year. Total RGNX earnings for the quarter were $22.71 million. In the same quarter last year, Regenxbio's earnings per share (EPS) was -$1.38.
As of the last Regenxbio earnings report, Regenxbio is currently losing money. Regenxbio's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$196.43 million, a 11.88% increase year over year.
What was RGNX's earnings growth in the past year?
As of Regenxbio's earnings date in Aug 6, 2026, Regenxbio's earnings has grown year over year. RGNX earnings in the past year totalled -$196.43 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.